Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

ClinicalTrials.gov ID: NCT00977522

Public ClinicalTrials.gov record NCT00977522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia Treated With A Stable Dose Of A Second Generation Antipsychotic

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.

Study identification

NCT ID
NCT00977522
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
207 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2009
Primary completion
Aug 31, 2010
Completion
Aug 31, 2010
Last update posted
Feb 6, 2012

2009 – 2010

United States locations

U.S. sites
37
U.S. states
13
U.S. cities
29
Facility City State ZIP Site status
Pfizer Investigational Site Cerritos California 90703
Pfizer Investigational Site Chula Vista California 91910
Pfizer Investigational Site Escondido California 92025
Pfizer Investigational Site Garden Grove California 92845
Pfizer Investigational Site Glendale California 91436
Pfizer Investigational Site Long Beach California 90805
Pfizer Investigational Site Long Beach California 90808
Pfizer Investigational Site National City California 91950
Pfizer Investigational Site Paramount California 90723
Pfizer Investigational Site Torrance California 90502
Pfizer Investigational Site Washington D.C. District of Columbia 20016
Pfizer Investigational Site Washington D.C. District of Columbia 20036
Pfizer Investigational Site Atlanta Georgia 30308
Pfizer Investigational Site Atlanta Georgia 30328
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Decatur Georgia 30333
Pfizer Investigational Site Park Ridge Illinois 60068
Pfizer Investigational Site Wichita Kansas 67207
Pfizer Investigational Site Wichita Kansas 67211
Pfizer Investigational Site Flowood Mississippi 39232
Pfizer Investigational Site Las Vegas Nevada 89102
Pfizer Investigational Site Las Vegas Nevada 89128
Pfizer Investigational Site Runnemede New Jersey 08078
Pfizer Investigational Site Toms River New Jersey 08755
Pfizer Investigational Site Willingboro New Jersey 08046
Pfizer Investigational Site Fresh Meadows New York 11366
Pfizer Investigational Site Holliswood New York 11423
Pfizer Investigational Site Staten Island New York 10304
Pfizer Investigational Site Staten Island New York 10305
Pfizer Investigational Site Edmond Oklahoma 73034
Pfizer Investigational Site Oklahoma City Oklahoma 73116
Pfizer Investigational Site Philadelphia Pennsylvania 19139
Pfizer Investigational Site Memphis Tennessee 38119
Pfizer Investigational Site Austin Texas 78731
Pfizer Investigational Site Austin Texas 78754
Pfizer Investigational Site Bellaire Texas 77401
Pfizer Investigational Site Houston Texas 77008

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00977522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 6, 2012 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00977522 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →